Literature DB >> 1905840

p53 mutations in human cancers.

M Hollstein1, D Sidransky, B Vogelstein, C C Harris.   

Abstract

Mutations in the evolutionarily conserved codons of the p53 tumor suppressor gene are common in diverse types of human cancer. The p53 mutational spectrum differs among cancers of the colon, lung, esophagus, breast, liver, brain, reticuloendothelial tissues, and hemopoietic tissues. Analysis of these mutations can provide clues to the etiology of these diverse tumors and to the function of specific regions of p53. Transitions predominate in colon, brain, and lymphoid malignancies, whereas G:C to T:A transversions are the most frequent substitutions observed in cancers of the lung and liver. Mutations at A:T base pairs are seen more frequently in esophageal carcinomas than in other solid tumors. Most transitions in colorectal carcinomas, brain tumors, leukemias, and lymphomas are at CpG dinucleotide mutational hot spots. G to T transversions in lung, breast, and esophageal carcinomas are dispersed among numerous codons. In liver tumors in persons from geographic areas in which both aflatoxin B1 and hepatitis B virus are cancer risk factors, most mutations are at one nucleotide pair of codon 249. These differences may reflect the etiological contributions of both exogenous and endogenous factors to human carcinogenesis.

Entities:  

Mesh:

Year:  1991        PMID: 1905840     DOI: 10.1126/science.1905840

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  1892 in total

1.  p53-mediated apoptosis is attenuated in Werner syndrome cells.

Authors:  E A Spillare; A I Robles; X W Wang; J C Shen; C E Yu; G D Schellenberg; C C Harris
Journal:  Genes Dev       Date:  1999-06-01       Impact factor: 11.361

2.  Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage.

Authors:  N H Chehab; A Malikzay; E S Stavridi; T D Halazonetis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

Review 3.  T cell receptor usage in malignant diseases.

Authors:  E Halapi; M Jeddi-Tehrani; A Osterborg; H Mellstedt
Journal:  Springer Semin Immunopathol       Date:  1999

Review 4.  Genetic alterations in head and neck cancer: interactions among environmental carcinogens, cell cycle control, and host DNA repair.

Authors:  C Y Fan
Journal:  Curr Oncol Rep       Date:  2001-01       Impact factor: 5.075

5.  A multivariate insight into the in vitro antitumour screen database of the National Cancer Institute: classification of compounds, similarities among cell lines and the influence of molecular targets.

Authors:  G Musumarra; D F Condorelli; A S Costa; M Fichera
Journal:  J Comput Aided Mol Des       Date:  2001-03       Impact factor: 3.686

6.  The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53.

Authors:  C Gobert; A Skladanowski; A K Larsen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

7.  The G(2) checkpoint is maintained by redundant pathways.

Authors:  T M Passalaris; J A Benanti; L Gewin; T Kiyono; D A Galloway
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

Review 8.  The clonal origin and clonal evolution of epithelial tumours.

Authors:  S B Garcia; M Novelli; N A Wright
Journal:  Int J Exp Pathol       Date:  2000-04       Impact factor: 1.925

Review 9.  Soft tissue sarcomas and p53 mutations.

Authors:  H Taubert; A Meye; P Würl
Journal:  Mol Med       Date:  1998-06       Impact factor: 6.354

10.  Analysis of p53-regulated gene expression patterns using oligonucleotide arrays.

Authors:  R Zhao; K Gish; M Murphy; Y Yin; D Notterman; W H Hoffman; E Tom; D H Mack; A J Levine
Journal:  Genes Dev       Date:  2000-04-15       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.